Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PLoS ONE - United States
doi 10.1371/journal.pone.0126988
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

PCN87 Cost Effectiveness Evaluation of Vemurafenib, an Orphan Drug for Braf Mutant Metastatic Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Development of Encorafenib for BRAF-mutated Advanced Melanoma

Current Opinion in Oncology
Cancer ResearchOncology
2018English

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

BRAF-mutated Metastatic Colorectal Cancer Between Past and Future

British Journal of Cancer
Cancer ResearchOncology
2015English

Thrombophilic Status May Predict Prognosis in Patients With Metastatic BRAFV600-mutated Melanoma Who Are Receiving BRAF Inhibitors

Journal of the American Academy of Dermatology
Dermatology
2016English

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Dermatology Research and Practice
Dermatology
2012English

Systemic Therapy for Previously Untreated Advanced BRAF-mutated Melanoma: Navigating a Shifting Landscape

Immunotherapy
OncologyAllergyImmunology
2017English

Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer

Current Oncology
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy